Drug Discovery and Delivery

The drug lasmiditan, which is used to treat migraines, shows promise as a possible treatment for acute kidney injury, according to a new study from the University of Arizona. The findings are published ahead of print in the American Journal of Physiology–Renal Physiology.

The article "Lasmiditan promotes recovery from acute kidney injury through induction of mitochondrial biogenesis” was highlighted by the American Journal of Physiology-Renal Physiology as an APSselect article for February.

Dr. Todd Vanderah professor and department head of the University of Arizona College of Medicine – Tucson’s Department of Pharmacology, was named an Alumni of the Year for 2023 by the University of Arizona Alumni Foundation.

Inventions from new Senior Members are making mining safer and greener, advancing treatments for cancer, and improving healthcare through better cameras and visualization.

Neurological disorders are the leading cause of disability and the second-leading cause of death worldwide, but UArizona researchers have developed a new class of drugs that is able to cross the blood-brain barrier and could be used to treat these degenerative neurological diseases and conditions.

Researchers in the UArizona Health Sciences Center for Innovation in Brain Science are investigating a drug that has the potential to reduce inflammation and increase the regeneration of nerve cells in people with ALS or Lou Gehrig’s disease.

Dr. Jianqin Lu, an assistant professor of pharmaceutics and pharmacokinetics at the University of Arizona R. Ken Coit College of Pharmacy, has received the Pharmaceutics Research Award from the American Association of Colleges of Pharmacy (AACP).

Collaboration between UArizona and Arizona State University has led researchers to develop a new drug that will block the development of Alzheimer's disease in Down Syndrome patients.

UArizona researchers have been working for decades to develop a drug that so specifically targets a deadly kind of breast cancer that there are little to no toxic side effects.

UArizona researchers have discovered a protein that is responsible for controlling cell growth in yeasts. Since humans and yeasts have remarkably similar cellular mechanisms, teasing out the differences presents drug developers with new targets for treatments.